Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Langerhans Cell Histiocytosis: early-phase trial registry

5 of 9 indexed Langerhans Cell Histiocytosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Langerhans Cell Histiocytosis: 9 US clinical trials tracked, 5 recruiting.

Langerhans Cell Histiocytosis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Carl Allen, running 1 of these trials.

Enrollment posture brief

Registry condition langerhans-cell-histiocytosis

OPEN 5 | RECR 56% | LATE 1 | EARLY 7 | RANK #1916 | SPON 1

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Langerhans Cell Histiocy (th…56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Langerhans Cell Histiocytosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Langerhans Cell Histiocytosis is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Langerhans Cell Histiocytosis trials is spread across many organizations.

    Carl Allen accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Langerhans Cell Histiocytosis enrolment sits around 90 participants.

    Median target enrolment is 90 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Langerhans Cell Histiocytosis research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 27Phase 31

Open and recent trials

9 total, page 1 of 1

RECRUITING 6,000 participants

Histiocytic Disorder Follow-up Study

University of Alabama at Birmingham

NCT05915208

RECRUITING Phase 2 1,400 participants

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

North American Consortium for Histiocytosis

NCT02205762

RECRUITING Phase 3 124 participants

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Baylor College of Medicine

NCT02670707

RECRUITING Phase 2 90 participants

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Carl Allen

NCT04079179

RECRUITING Phase 2 75 participants

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Cook Children's Health Care System

NCT06582745

ACTIVE NOT RECRUITING Phase 2 1,376 participants

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

NCT03155620

ACTIVE NOT RECRUITING Phase 2 25 participants

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Dana-Farber Cancer Institute

NCT02425904

COMPLETED Phase 2 17 participants

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

GlaxoSmithKline

NCT01395004

COMPLETED Phase 2 5 participants

Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH

Memorial Sloan Kettering Cancer Center

NCT00588536

Phase Distribution

PhaseTrial count
Phase 2 7
Phase 3 1

Named interventions

Most-linked intervention names on Langerhans Cell Histiocytosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Methotrexate Drug
2 trials
6-Thioguanine Drug
1 trials
GSK2110183 Drug
1 trials
Clofarabine Drug
1 trials
Vinblastine/prednisone Drug
1 trials
Cobimetinib Drug
1 trials
INDOMETHACIN Drug
1 trials
mercaptopurine Drug
1 trials

US sites by state

Facility locations filed on Langerhans Cell Histiocytosis trials. A trial with sites in several states counts in each.

Texas 5 trials
California 5 trials
New York 4 trials
Massachusetts 4 trials
Arizona 4 trials
Arkansas 4 trials
Maryland 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Langerhans Cell Histiocytosis page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Langerhans Cell Histiocytosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Carl Allen sponsors the most Langerhans Cell Histiocytosis trials on record, review their full trial history before evaluating a specific study. See Carl Allen's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Langerhans Cell Histiocytosis condition card totals 9 registered trials; most-linked intervention Methotrexate; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.